Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Tipranavir/Ritonavir and Rifabutin in Healthy Volunteers
NCT02251171Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2003
- Primary completion
- Oct 2003
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of tipranavir in human immunodeficiency virus infection (HIV), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum plasma concentration up to 144 hours, Plasma concentration at 12 hours and 2 more. Started Aug 2003; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02251171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02251171.